Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Aquestive Therapeutics (AQST) reported a Q3 loss of $0.13 per share, slightly worse than the Zacks Consensus Estimate of a $0.12 loss. However, the company exceeded revenue expectations.
November 05, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Aquestive Therapeutics reported a Q3 loss of $0.13 per share, missing the Zacks Consensus Estimate by $0.01. Despite the earnings miss, the company exceeded revenue expectations.
The earnings per share (EPS) was slightly worse than expected, which could negatively impact the stock price. However, exceeding revenue expectations may offset this negative impact, leading to a neutral short-term effect on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100